Abstract:Cardiac hypertrophy is initially an adaptive response to increased hemodynamic workload or defective contractile machinery; however, in the long‐term, it contributes to heart failure and sudden cardiac death. The extracellular regulatory factors and intracellular signaling pathways involved are not fully clear. Here, we studied the chronic effect of Ang II infusion on cardiac hypertrophy and fibrosis, and evaluated the role of class I PI3‐kinase in these actions of Ang II using lentiviral vector‐mediated expression of a dominant negative form of Class I PI3‐kinase subunit p85α in the heart of rats. Subcutaneous 4‐week infusion of Ang II induced severe cardiac hypertrophy and perivascular fibrosis in the heart. Cardiac transduction of Lv‐DNp85 abolished Ang II‐induced phosphorylation of Akt in the heart, as well as Ang II‐induced cardiac hypertrophy and perivascular fibrosis. Next, we examined intracellular mechanisms underlying Ang II‐induced cardiac hypertrophy in cultured cardiomyocytes. It is well known that mitochondrial oxidative stress mediates Ang II‐induced cardiac hypertrophy and the major source of reactive oxygen species (ROS), damaged mitochondria, is cleared by autophagy (also called mitophagy) in cardiac myocytes. Treatment of cardiomyocytes with Ang II (10−9 to 10−5 M) significantly increased autophagy with two phases (increases at low doses, decreases at high doses, peaked at 10−7 M). Ang II (10−6 M)‐induced increases in autophagy were significantly potentiated by PI3‐kinase Class I inhibitor, LY294002 (1 μM) and dramatically attenuated by 3‐Methyladenine (3‐MA, 1 μM), a PI3‐kinase Class III inhibitor. Ang II‐induced mitochondrial ROS production, measured using MitoSOX, was attenuated by LY294002 and potentiated by 3‐MA significantly. PI3‐kinases activity were measured using ELISA in cardiomyocytes, demonstrating that Ang II (10−6 M, i.e. high dose) significantly increased the activity of both Class I and Class III PI3‐kinases; however, Ang II (10−9 M, i.e. low dose) selectively elevated PI3‐kinase Class III activity. Together these data suggest that Ang II could have dual effects in the heart: 1) a protective arm to prevent ROS over‐generation in physiological cardiac hypertrophy, which is mediated by a Class III PI3‐kinase/autophagy‐dependent pathway; and 2) a deleterious arm due to increased mitochondrial ROS production through inhibition of autophagy by a Class I PI3‐kinase pathway in cardiomyocytes.Support or Funding InformationSupported by NIH NS55008.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Research Development on Regulation of Cardiac Physiological Hypertrophy by the IGF-PI3K-Akt Signaling Pathway

Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway

Increased Myocardial Stiffness Activates Cardiac Microvascular Endothelial Cell Via VEGF Paracrine Signaling in Cardiac Hypertrophy

Research on Regulation of Cardiac Hypertrophy by the PI3K Signaling at Long-term High Intensity Exercise

Research on Regulation of Cardiac Hypertrophy by the Akt /mTOR signaling at Different Exercise Intensity

Signaling Pathways in Cardiac Hypertrophy

Class Iii Pi3k-Mediated Prolonged Activation Of Autophagy Plays A Critical Role In The Transition Of Cardiac Hypertrophy To Heart Failure

Class III PI3‐Kinase in Angiotensin II‐Induced Cardiac Hypertrophy

Transforming growth factor-β and bone morphogenetic protein signaling pathways in pathological cardiac hypertrophy

Regulation of Phosphoinositide 3-kinases on the Heart

The Cellular Signal Transduction and Genetic Expression of Cardiac Hypertrophy

IGF1-PI3K-induced physiological cardiac hypertrophy: Implications for new heart failure therapies, biomarkers, and predicting cardiotoxicity

Ca2+—Dependent Signaling Pathways Through Calcineurin and Ca2+ Calmodulin—Dependent Protein Kinase in Development of Cardiac Hypertrophy

ATF3 Regulates Multiple Targets and May Play a Dual Role in Cardiac Hypertrophy and Injury.

Regression of pathological cardiac hypertrophy: Signaling pathways and therapeutic targets

Role of PI3‐kinase in Angiotensin II‐induced Cardiac Hypertrophy: Shift from Class III to Class I

Inhibitory Molecules in Signal Transduction Pathways of Cardiac Hypertrophy

PKB/Akt signaling in cardiac development and disease

Role of extracellular signal-regulated kinase 1/2 signaling underlying cardiac hypertrophy

Novel Role for Pleckstrin Homology-Like Domain Family A, Member 3 in the Regulation of Pathological Cardiac Hypertrophy.

Advance of PKC Signaling Pathway in Exercise-induced Cardiac Myocyte Hypertrophy